KCM
TRIB

Kennedy Capital Management’s Trinity Biotech TRIB Stock Holding History

Kennedy Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-654
Closed -$551K – 775
2017
Q3 		$551K Buy
+654
New +$547K 0.01% 705
2016
Q2 		– Sell
-1,636
Closed -$2.86M – 747
2016
Q1 		$2.86M Sell
1,636
-690
-30% -$1.1M 0.06% 510
2015
Q4 		$4.1M Sell
2,326
-2,789
-55% -$4.94M 0.08% 422
2015
Q3 		$8.78M Buy
5,115
+149
+3% +$360K 0.18% 194
2015
Q2 		$13.5M Sell
4,966
-139
-3% -$361K 0.24% 105
2015
Q1 		$14.7M Sell
5,105
-153
-3% -$424K 0.26% 103
2014
Q4 		$13.8M Buy
5,258
+2,450
+87% +$6.33M 0.25% 108
2014
Q3 		$7.69M Buy
2,808
+113
+4% +$367K 0.15% 252
2014
Q2 		$9.31M Buy
2,695
+15
+0.6% +$53.3K 0.17% 211
2014
Q1 		$9.74M Sell
2,680
-188
-7% -$739K 0.18% 198
2013
Q4 		$10.8M Hold
2,868
– – 0.2% 172
2013
Q3 		$9.36M Buy
2,868
+165
+6% +$483K 0.18% 197
2013
Q2 		$6.83M Buy
+2,703
New +$6.73M 0.14% 279

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return

Kennedy Capital Management's TRIB Position: Q4 2017 in Review

Kennedy Capital Management sold out of Trinity Biotech (TRIB) in Q4 2017, closing a stake of 654 shares — an estimated $551K sold.

Kennedy Capital Management first reported a position in TRIB in Q2 2013 and held it in 13 quarters. The position peaked at $14.7M in Q1 2015. 47 funds tracked by Wall St. Rank hold TRIB as of Q4 2017.

  • Kennedy Capital Management reported no remaining Trinity Biotech position as of Q4 2017 after selling out during the quarter.
  • Kennedy Capital Management sold 654 Trinity Biotech shares in Q4 2017, an estimated $551K.
  • Kennedy Capital Management first reported a position in Trinity Biotech in Q2 2013 and held it in 13 quarters.
  • Kennedy Capital Management's Trinity Biotech position peaked at $14.7M in Q1 2015.
  • 47 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2017.

Based on Kennedy Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.